- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 798 of 2,219.
| EudraCT Number: 2012-002427-15 | Sponsor Protocol Number: 105910 | Start Date*: 2015-06-01 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, partially double-blind clinical trial to evaluate the immu-nogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as co... | ||
| Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis diseases and, if applicable, Haemophilus influenzae type b disease. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2014-002187-32 | Sponsor Protocol Number: DMSG03/14 | Start Date*: 2014-09-05 |
| Sponsor Name:Danish Myeloma Study Group | ||
| Full Title: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagno... | ||
| Medical condition: multiple myeloma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-001640-38 | Sponsor Protocol Number: ATTRACT | Start Date*: 2014-08-08 | |||||||||||
| Sponsor Name:CHU DE POITIERS | |||||||||||||
| Full Title: Efficacy of Aflibercept (Eylea®) on Type 3 choroidal neovascularization. | |||||||||||||
| Medical condition: Retinal diseases (type 3 choroidal neovascularization) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-000406-35 | Sponsor Protocol Number: UX023-CL201 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Ultragenyx Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Randomized, open Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the anti-FGF23 antibody, KRN23, in Pediatric Patients with X-linked Hypophosphatemia (XLH) | |||||||||||||
| Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, and the most common heritable form of rickets. In XLH patients, high circulating levels of fibroblast growth factor 23 (FG... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) NL (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-004768-38 | Sponsor Protocol Number: 6096A1-012 | Start Date*: 2015-04-12 |
| Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | ||
| Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Rout... | ||
| Medical condition: Pneumococcal disease | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001543-36 | Sponsor Protocol Number: 107625 | Start Date*: 2015-06-22 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, double-blind, randomised, placebo-controlled, multi-centre study in Japan to assess the efficacy, safety, reactogenicity and immunogenicity of the lyophilised formulation of GlaxoSmith... | ||
| Medical condition: Healthy volunteers | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2011-005939-78 | Sponsor Protocol Number: C-II-008 | Start Date*: 2012-06-25 | |||||||||||
| Sponsor Name:CESAR Central European Society for Anticancer Drug Research-EWIV | |||||||||||||
| Full Title: A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study) | |||||||||||||
| Medical condition: metastatic renal cell carcinoma (mRCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001039-18 | Sponsor Protocol Number: PRGNS-11-02-KOR | Start Date*: 2015-07-03 |
| Sponsor Name:Astellas Pharma Korea, Inc. | ||
| Full Title: Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf [Cap.]®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Cortic... | ||
| Medical condition: Minimal change nephrotic syndrome | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-004637-47 | Sponsor Protocol Number: EFC6132,HMR3647B/3002 | Start Date*: 2015-03-17 | |||||||||||
| Sponsor Name:Sanofi-aventis | |||||||||||||
| Full Title: Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 ... | |||||||||||||
| Medical condition: Otitis Media, Suppurative Otitis Media, Purulent | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004640-35 | Sponsor Protocol Number: EFC11681 | Start Date*: 2015-03-17 | |||||||||||
| Sponsor Name:Sanofi | |||||||||||||
| Full Title: A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus® (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diab... | |||||||||||||
| Medical condition: Type 1 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004644-35 | Sponsor Protocol Number: PKD10491 | Start Date*: 2015-03-17 | |||||||||||
| Sponsor Name:Sanofi-aventis | |||||||||||||
| Full Title: Single dose, open label safety, tolerability, pharmacokinetic and pharmacodynamic evaluation of three different eplivanserin doses in children aged 6-17 years with insomnia of various origins | |||||||||||||
| Medical condition: Sleep Initiation and Maintenance Disorders | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000277-12 | Sponsor Protocol Number: 38518168PSO2001 | Start Date*: 2015-04-28 | |||||||||||
| Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
| Full Title: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects with Moderate to Severe Plaquetype Psoriasis | |||||||||||||
| Medical condition: Moderate to severe plaque-type psoriasis. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002644-40 | Sponsor Protocol Number: B3451002 | Start Date*: 2015-05-27 | ||||||||||||||||
| Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
| Full Title: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus Aureus 4-Antigen Vaccine (SA4Ag) in Adults Undergoing Elective Posterior Instrum... | ||||||||||||||||||
| Medical condition: Prophylaxis for prevention of Post-operative S. aureus infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) HU (Completed) AT (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2014-000706-34 | Sponsor Protocol Number: A3921237 | Start Date*: 2014-10-06 | |||||||||||
| Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (C... | |||||||||||||
| Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001650-15 | Sponsor Protocol Number: EMR700773-510 | Start Date*: 2015-06-26 |
| Sponsor Name:Merck Serono Middle East FZ-LLC | ||
| Full Title: A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age Wi... | ||
| Medical condition: Phenylketonuria | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2014-004077-16 | Sponsor Protocol Number: 14/0249 | Start Date*: 2014-12-03 | |||||||||||
| Sponsor Name:University College London Joint Research Office | |||||||||||||
| Full Title: A Phase IV randomised controlled trial of the selective serotonin reuptake inhibitor Sertraline versus Cognitive Behavioural Therapy for anxiety symptoms in people with Generalised Anxiety Disorder... | |||||||||||||
| Medical condition: Generalised anxiety disorder (GAD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001826-61 | Sponsor Protocol Number: 11‐HM10560A‐201 | Start Date*: 2011-07-29 | |||||||||||
| Sponsor Name:Hanmi Pharmaceutical Co., Ltd. | |||||||||||||
| Full Title: A phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a Long-acting rhGH-HMC001 conjugate in treatment of subjects suffering from adult growth hormone defic... | |||||||||||||
| Medical condition: Adult growth hormone deficiency (AGHD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000456-15 | Sponsor Protocol Number: 3518 | Start Date*: 2015-05-19 | |||||||||||
| Sponsor Name:Kings College London [...] | |||||||||||||
| Full Title: The prevention of pre-term birth in women who develop a short cervix. A multi-centre randomised controlled trial to compare three treatments; cervical cerclage, cervical pessary and vaginal proges... | |||||||||||||
| Medical condition: Short Cervix in Pregnancy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000159-26 | Sponsor Protocol Number: D2274C00001 | Start Date*: 2015-07-06 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients with Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After at Least One Line of... | ||
| Medical condition: Squamous Non-Small Cell Lung Cancer | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-022133-28 | Sponsor Protocol Number: AMAG-FER-CKD-401 | Start Date*: 2013-08-12 | |||||||||||
| Sponsor Name:AMAG Pharmaceuticals, Inc. | |||||||||||||
| Full Title: Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, with MRI Substudy, of Repeated Doses of Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Defic... | |||||||||||||
| Medical condition: Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.